Skip to nav Skip to content
Patrick  Grogan

Patrick Grogan, MD, PhD

4.9 (142)

Specialty: Medical Oncology

Program: Neuro-Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Brain Cancer, Glioblastoma, Meningioma

    Dr. Grogan received his PhD in Pharmacology and MD from the University of Kansas School of Medicine. He then completed an Internal Medicine Residency followed by a Physician-Scientist Training Program/Medical Oncology Fellowship (Neuro-Oncology Track) at the University of Wisconsin Hospitals and Clinics. Dr. Grogan joins Moffitt from the University of Wisconsin School of Medicine and Public Health, where he was a Faculty Clinical Instructor in Neuro-Oncology and Medical Oncology, Department of Medicine, and a Research Associate and Postdoctoral Research Fellow in the Department of Oncology, McArdle Laboratory for Cancer Research.Dr. Grogan specializes in the management of central nervous system malignancies, with a focus on treating patients with primary CNS cancers including both low- and high-grade gliomas.  His clinical interests include precision and individualized treatment strategies for patients with high-grade gliomas while also focusing heavily on quality-of-life considerations.

  • Participating Trials

    Clinical Trial 20110
    GBM Agile: Global Adaptive Trial Master Protocol
    Condition: Neurologic Oncology
    Intervention: ADI-PEG 20 (); BAY 73-4506 (Regorafenib); Lomustine (CeeNU); Paxalisib (); Regorafenib (Stivarga); Temodal (Temozolomide); Temozolomide (); Troriluzole (); VAL-083 (); VT1021 ()
    Status: Open

    Clinical Trial 22078
    ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
    Condition: Neurologic Oncology
    Intervention: ONC201 (); Placebo ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Harari CM, Burr AR, Morris BA, Tomé WA, Bayliss A, Bhatia A, Grogan PT, Robins HI, Howard SP. Pulsed reduced-dose rate re-irradiation for patients with recurrent grade 2 gliomas. Neurooncol Adv. 2024 May.6(1):vdae073. Pubmedid: 38845694. Pmcid: PMC11154132.
    • Grogan PT, Helgager JJ, Deming DA, Howard SP, Jenkins RB, Robins HI. Case report: Radiographic complete response of radiation-induced glioblastoma to front-line radiotherapy: A report and molecular characterization of two unique cases. Front Neurol. 2023 Mar.14:1099424. Pubmedid: 37025206. Pmcid: PMC10070702.
    • Grogan PT, Deming DA, Helgager J, Ruszkiewicz T, Baskaya MK, Howard SP, Robins HI. Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma. Neurooncol Adv. 2022 Apr.4(1):vdac046. Pubmedid: 35673607. Pmcid: PMC9167633.
    • Subramanian C, Grogan PT, Wang T, Bazzill J, Zuo A, White PT, Kalidindi A, Kuszynski D, Wang G, Blagg BSJ, Cohen MS. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition. Mol Oncol. 2020 Sep.14(9):2058-2068. Pubmedid: 32255264. Pmcid: PMC7463342.
    • Sharifi MN, Anandan A, Grogan P, O'Regan RM. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer. 2020 Aug.126(15):3400-3416. Pubmedid: 32426848.
    • Johnson KA, DeStefanis RA, Emmerich PB, Grogan PT, Kratz JD, Makkar SK, Clipson L, Deming DA. Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection. CURR TREAT OPTION ON. 2020 Apr.21(5):35. Pubmedid: 32328818. Pmcid: PMC7924903.
    • Subramanian C, Grogan PT, Opipari VP, Timmermann BN, Cohen MS. Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-κB activation. Oncotarget. 2018 Mar.9(18):14509-14523. Pubmedid: 29581860. Pmcid: PMC5865686.
    • Nguyen HTN, Grogan P, Robins HI. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited. Lancet Oncol. 2017 Dec.18(12):e708. Pubmedid: 29208432.
    • Sim MW, Grogan PT, Subramanian C, Bradford CR, Carey TE, Forrest ML, Prince ME, Cohen MS. Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. Laryngoscope. 2016 May.126(5):E184-E190. Pubmedid: 26690734. Pmcid: PMC4842141.
    • Zhao J, Zhao H, Hall JA, Brown D, Brandes E, Bazzill J, Grogan PT, Subramanian C, Vielhauer G, Cohen MS, Blagg BS. Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm. 2014 Sep.5(9):1317-1323. Pubmedid: 25328661. Pmcid: PMC4198308.
    • Cao CM, Zhang H, Gallagher RJ, Day VW, Kindscher K, Grogan P, Cohen MS, Timmermann BN. Withanolides from Physalis hispida. J Nat Prod. 2014 Mar.77(3):631-639. Pubmedid: 24456028.
    • Grogan PT, Sarkaria JN, Timmermann BN, Cohen MS. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs. 2014 Aug.32(4):604-617. Pubmedid: 24718901. Pmcid: PMC4380174.
    • Zhang H, Bazzill J, Gallagher RJ, Subramanian C, Grogan PT, Day VW, Kindscher K, Cohen MS, Timmermann BN. Antiproliferative withanolides from Datura wrightii. J Nat Prod. 2013 Mar.76(3):445-449. Pubmedid: 23252848. Pmcid: PMC3606642.
    • Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neurooncol. 2013 Jun.15(6):735-746. Pubmedid: 23479134. Pmcid: PMC3661094.
    • Grogan PT, Sleder KD, Samadi AK, Zhang H, Timmermann BN, Cohen MS. Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs. 2013 Jun.31(3):545-557. Pubmedid: 23129310. Pmcid: PMC3677827.
    • Nadkarni A, Shrivastav M, Mladek AC, Schwingler PM, Grogan PT, Chen J, Sarkaria JN. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J Neurooncol. 2012 Dec.110(3):349-357. Pubmedid: 23054561. Pmcid: PMC3535329.
    • Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, Robertson PT, Liang X, Chen W, Parney IF, Hunt MA, Blazar BR, Ohlfest JR. Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res. 2011 Nov.71(21):6583-6589. Pubmedid: 21908554. Pmcid: PMC3360979.
    • Olin MR, Andersen BM, Zellmer DM, Grogan PT, Popescu FE, Xiong Z, Forster CL, Seiler C, SantaCruz KS, Chen W, Blazar BR, Ohlfest JR. Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res. 2010 Oct.16(19):4800-4808. Pubmedid: 20858839. Pmcid: PMC3016438.
    • Staley J, Grogan P, Samadi AK, Cui H, Cohen MS, Yang X. Growth of melanoma brain tumors monitored by photoacoustic microscopy. J Biomed Opt. 2010 Jul.15(4):040510. Pubmedid: 20799777.
    • Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine. 2010 Apr.28(19):3371-3378. Pubmedid: 20197146. Pmcid: PMC2854671.
    • Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009 Sep.75(1):212-219. Pubmedid: 19695438. Pmcid: PMC2773462.
    • Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol. 2009 Mar.92(1):23-31. Pubmedid: 19011762. Pmcid: PMC2790867.
    • Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neurooncol. 2009 Jun.11(3):281-291. Pubmedid: 18952979. Pmcid: PMC2718972.
    • Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther. 2009 Feb.8(2):407-414. Pubmedid: 19174557. Pmcid: PMC2692390.
    • Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res. 2008 Jun.14(12):3993-4001. Pubmedid: 18559622. Pmcid: PMC3972037.
    • Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007 Mar.6(3):1167-1174. Pubmedid: 17363510.
    • Sarkaria JN, Schwingler P, Schild SE, Grogan PT, Mladek AC, Mandrekar SJ, Tan AD, Kobayashi T, Marks RS, Kita H, Miller RC, Limper AH, Leof EB. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol. 2007 Aug.2(8):751-757. Pubmedid: 17762343.
    • Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006 Apr.12(7 Pt 1):2264-2271. Pubmedid: 16609043.
  • Patient Comments

    Overall Satisfaction

    4.9

    142 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor